Zelira Therapeutics Limited
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Zelira Therapeutics Limited (ASX:ZLD; OTCQB:ZLDAF) is a biopharmaceutical company focused on the research, development and commercialization of cannabinoid-based medicines for treating medical conditions including insomnia, autism spectrum disorder, chronic non-cancer pain and diabetic nerve pain. The company offers proprietary revenue-generating products such as the HOPE brand formulations for autism launched in multiple US states; ZTL-106 for musculoskeletal injury; ZLT-L-007, which demonstrated superior pain reduction compared to Lyrica in a 2023 clinical trial; cannabidiol/dronabinol combinations for sleep disorders; and a pipeline encompassing preclinical candidates for diabetes, dementia and pancreatic cancer, alongside over-the-counter products for dermatology, oral care and neuropathies, plus platform technologies like enhanced drug delivery capsules for improved bioavailability. Zelira Therapeutics, founded in 2003 and headquartered in Perth, Australia, operates principally in Australia and the United States, with global market access strategies involving licensing and distribution partnerships; it conducts clinical trials in collaboration with institutions including Curtin University, Telethon Kids Institute, University of Western Australia, St. Vincent’s Hospital and Children’s Hospital of Philadelphia. Recent developments include securing a US$1 million at-the-market funding facility and A$1.07 million under the R&D Tax Incentive Scheme in 2025; creating a special purpose vehicle with US$8.6 million cornerstone funding from Cantheon Capital LLC to support Phase 2/3 US FDA trials for HOPE products; advancing FDA pre-IND meetings; reporting positive top-line results from diabetic nerve pain trials in 2023; and providing 2025 milestone updates emphasizing clinical and commercial expansion.
Zelira Therapeutics (OTCMKTS:ZLDAF) and Hyperion DeFi (NASDAQ:HYPD) Critical Analysis
Zelira secures transformative US$33 million funding for HOPE® 1 autism program
Zelira Therapeutics (OTCMKTS:ZLDAF) Trading Up 13.9% – Here’s Why
Zelira Therapeutics (OTCMKTS:ZLDAF) Trading Down 4.4% – Here’s What Happened
Zelira Therapeutics well placed to generate further growth in cash flow as commercialisation accelerates
Zelira Therapeutics receives A$1.292 million cash R&D tax incentive
Zelira Therapeutics receives 25% of US$1 million licensing fee from DRCN Holdings for EDCDM technology
Zelira Therapeutics' Phase 1 dose escalation study in chronic pain patients on long-term opioid treatment published in peer-reviewed journal
Zelira Therapeutics expands into growing New Zealand cannabinoid-based medicines market
Zelira Therapeutics gets ethics green light for Phase 2a trial of sports injury cannabinoid
Zelira Therapeutics develops enhanced solid-form cannabinoid production method, signs foundational licensing deal
Zelira Therapeutics research-backed products behind its impressive growth
Zelira Therapeutics gains substantial new US-based shareholder following US$5 million cap raise
Zelira Therapeutics set to launch suite of new cannabinoid-based products over FY22 and grow sales of existing products
Zelira™ Launches RAF FIVE™ Acne Treatment Products Through Its Dermatology Focused Subsidiary
Zelira Therapeutics launches RAF FIVE™ CBD acne treatment products
Zelira Therapeutics expands into large German market via exclusive cannabis distribution agreement
Zelira Therapeutics' commercialisation program to see launch of suite of new cannabinoid-based products over FY22
Zelira Therapeutics closes out FY21 with record cash receipts ahead of product launches
Zelira Therapeutics to go head-to-head with big pharma in US clinical pain trial